The long-term restless legs syndrome management plan

Restless legs: a plain-language guide for people already on medication

The patient version of docs/SOLUTION_PROTOCOL.md, for someone who has had restless legs syndrome (RLS) for years, takes a tablet every evening, and suspects it is not working as well as it used to. Each recommendation carries an evidence tag: A (pooled trials), B (one good trial or large study), C (small or observational), D (expert consensus only).

---

Please read this first

Medical disclaimer. RLS is a chronic neurological condition. No cure is claimed here, and nothing in this guide is individual medical advice. Every factual statement is tied to a published study in our knowledge base, with an evidence grade attached, so you can see how strong it is. Dopamine-agonist withdrawal and augmentation are dangerous when mishandled: any change to medication must happen only under physician supervision, and a dopamine agonist must never be stopped abruptly. Where this guide separates established evidence from emerging evidence from our own simulation's hypotheses, take that separation seriously — simulation output is never evidence.

---

Part 1 — What RLS is actually doing in your brain

It starts with iron — but not the iron in your blood count. The best-supported explanation is that the brain regions controlling movement do not hold on to iron as they should. You can be entirely non-anaemic and still be short where it matters. Iron is the cofactor the brain needs to make dopamine, so a local shortage quietly changes how dopamine signalling behaves. The genes that carry RLS risk in families — MEIS1, BTBD9, PTPRD — are iron-handling and neural-development genes, which is why RLS runs in families and why the tendency does not disappear after a course of iron. Honesty note: this is the field's working model, not a settled fact. The largest MRI study to date, pooled with everything before it, found no overall evidence of lower brain iron, with signs of publication bias in the older literature (A). The spinal-fluid and autopsy evidence still supports it. So: strong hypothesis, contested measurement.

Then dopamine goes out of rhythm — not simply "low". RLS is not a dopamine deficiency like Parkinson's; that is the thing patients are most often told wrongly. It looks more like a system running too hot by day and crashing in the evening: more dopamine made and released, and in response the receiving side turns its receptors down. Dopamine dips at night in everyone — but in a system that has already turned its receptors down, that ordinary dip lands much harder. That is why symptoms obey the clock — worst around midnight to 01:00, easiest around 09:00–11:00 (C) — and why a diary recording the clock time of onset beats one recording severity alone.

And the whole system is over-aroused and under-braked. Adenosine — the brain's own "slow down" signal, the one caffeine blocks — appears to work weakly at its A1 receptors, leaving glutamate, the accelerator, unopposed. That is the arousal half of RLS: the reason your mind is wide awake at 23:00 as well as your legs. Meanwhile the spinal cord's reflex circuits become hyperexcitable, which is where the leg movements and the irresistible urge to move are generated. Movement relieves it briefly because it feeds sensory input back into those circuits. Put the three together — iron, mistimed dopamine, unbraked arousal — and you get a condition that is worst at rest, worst at night, and eased by moving. (This is the picture modelled in simulation/; that model illustrates mechanism and is explicitly not evidence for any treatment.)

---

Part 2 — Why your medication may have stopped working

If you take pramipexole (Sifrol, Mirapexin), ropinirole or rotigotine, there is a specific complication called augmentation — the drug itself driving symptoms harder over time. It is not your disease progressing. Roughly 7–10% of people on these drugs develop it each year (D), and that compounds: 42% over eight years in one specialist cohort (C).

The signs to check yourself against (D): symptoms starting earlier in the day than they used to — a shift of about four hours is the single clearest sign; symptoms spreading to your arms or trunk; needing to move sooner once you sit still; the tablet wearing off faster; and symptoms getting worse after a dose increase.

That last one is the trap. Raising the dose to chase worsening symptoms is the most damaging mistake in this condition — every guideline reviewed says so (D). It feels like the obvious move; it feeds the problem.

Guidance has shifted accordingly: in 2025 the American Academy of Sleep Medicine recommended against pramipexole, ropinirole and rotigotine as standard therapy, because of augmentation (D). That is not a reason to panic or to stop — it is a reason to book a proper review.

Two more things worth raising unprompted, because clinicians often do not ask: impulse-control problems (gambling, shopping, binge eating, hypersexuality) occurred in around 7–10% of people on these drugs in two cohorts, and about 10% of long-term users reported falling asleep at the wheel (C).

---

Part 3 — The plan, step by step

Step 0 — Prepare (about four weeks). D

Start a diary: every night, the time symptoms began (the important one), where in the body, severity 0–10, medication and time, alcohol, any new medicine (C). Get a baseline IRLS score (0–40) from your doctor. Then agree a written plan before anything changes. Structure is not a formality — in ordinary practice 85% of augmented patients simply stay on the agonist and only one in five is dose-reduced, whereas guideline-led programmes reach around 78% responders (C).

Step 1 — Fix your iron. A for the treatment, D for the thresholds

Ask for ferritin and transferrin saturation (TSAT), drawn in the morning, at least 24 hours after any iron tablet. Three separate national and international guidelines converge on the same trigger: ferritin at or below 75, or TSAT under 20% (D).

• Tablets: about 65 mg of elemental iron, every other day, one morning dose, with vitamin C, away from milk, tea and coffee. Alternate-day dosing is not folklore — a daily dose above roughly 60–100 mg switches on a blocking hormone for about 24 hours and sabotages the next dose (B). Expect a real but modest benefit, on average smaller than the placebo response seen in RLS trials (A).
• Intravenous iron (ferric carboxymaltose, 1000 mg total) is stronger, and is what the guidelines point to when ferritin is 75–100. In the largest trial, recipients needed rescue medication far less often — 33% versus 59%, about one in four people spared; in a smaller trial 37.5% were off medication at 30 weeks (B). Not a guaranteed ticket off medication.
• Two hard rules. Do not judge IV iron at four weeks — the trial that missed at week 4 succeeded at week 12 (B). And have your phosphate checked before and after each infusion: this particular iron drops phosphate below the safe line in about half of recipients (B).

Step 2 — Take away what is making it worse. A/B — best return for least risk

Two drugs cause most drug-triggered RLS: mirtazapine and quetiapine, usually within a day or two of a start or dose change (B). Metoclopramide (for nausea) is a third (C). Stomach-acid drugs matter too — proton-pump inhibitors are linked to RLS in two national studies, H2-blockers in one of the two (B).

Two things to raise specifically:

• Antidepressants: never stop one on your own, and do not accept a blanket ban either. Bupropion has the best RLS record (A); SSRIs were the one class not flagged in the largest safety database (C). Mirtazapine is the one to question.
• Melatonin bought over the counter: in a small unblinded study of eight people, 3 mg in the early evening made leg movements worse (C). Small, but the direction is wrong and almost nobody makes the connection themselves.

Step 3 — Change medication, if that is the right call. C/D — supervised only

This is the part that must be your doctor's, not yours. Three principles:

1. Add before you subtract. Get the replacement working at an effective dose before reducing the agonist. Even small reductions can cause severe rebound (D).
2. The destination is usually an alpha-2-delta drug — gabapentin, pregabalin, or gabapentin enacarbil where available. Head-to-head over a year, augmentation was 2.1% on pregabalin versus 7.7% on pramipexole (B). Beside that benefit, honestly: that same trial recorded six cases of suicidal thinking on pregabalin versus two or three on pramipexole.
3. There is no published taper schedule. No trial has compared taper speeds, and no guideline in our knowledge base gives a percentage or an interval (D). Any specific number you read online — including the widely repeated "reduce by 10–25% every few weeks" — is untraceable. Your prescriber sets the steps: small, and held until things resettle.

Step 4 — Keep going, and know when staying on a drug is right. C/D

Review every three months for a year, then twice a year: severity score, diary onset time, ferritin and TSAT, kidney function, mood, impulse control, falls, driving. Iron handling looks like a lasting trait rather than a one-time fix, so repletion may need repeating (E).

"Off all drugs" is not the goal. If symptoms stay moderate or severe after iron is corrected, aggravators removed and the evening routine established, medication is the right answer — and an alpha-2-delta drug that works does not need tapering to prevent augmentation, since no reviewed trial links that class to augmentation.

---

Part 4 — The evening toolkit

Use this from day one, not after the taper, concentrated in the hours when you are vulnerable.

1. Nerve stimulation at the calf (TOMAC) — the only non-drug therapy recommended by AASM 2025; 45% responded versus 16% on sham (B). Caveat: the pooled effect across trials sits below what an individual would notice, and the research is largely manufacturer-funded.
2. Structured exercise — aerobic plus resistance, 3x/week, at least 12 weeks (B). In one dialysis study it roughly matched low-dose ropinirole. A standing programme, not a last-minute bedtime workout.
3. Heat or cold on the legs — the cheapest option available anywhere (C for ordinary RLS). The large pooled effect often quoted comes mostly from dialysis patients; safe and cheap to try, but do not expect that magnitude.
4. Pneumatic compression sleeves — one good sham-controlled trial (B), not recommended by the German 2024 guideline. Contested, not dismissed.
5. CBT for insomnia and progressive muscle relaxation (B). Caution: CBT-I's sleep restriction component has never been tested in RLS and sleep loss worsens leg symptoms — ask for a higher floor on time in bed.
6. Avoid long motionless evenings — leg oxygen falls during immobility, tracking severity (B).

Not supported: acupuncture (A, negative), cortical tDCS (B, negative), vitamin D (B, negative). No RLS evidence exists at all for weighted blankets or mindfulness — different from useless; nobody has looked.

---

Part 5 — What to ask your doctor

• "Can we check ferritin and transferrin saturation? The AASM 2025 guideline, the IRLSSG 2018 iron guideline and the German DGN/DGSM 2024 guideline all use a ferritin threshold of 75."
• "Do I meet the Max Planck augmentation criteria? My symptoms now start at ___ instead of ___."
• "AASM 2025 recommends against dopamine agonists as standard therapy — does that change my plan?"
• "Which of my other medicines could be making this worse — mirtazapine, quetiapine, metoclopramide, my stomach-acid tablet?"
• "If we reduce the agonist, what replaces it first, and what do I do if the first week is bad?"
• "Can we agree a written plan, with the stop signs on it?"

Patient organisations publishing guideline summaries you can bring: RLS e.V. (restless-legs.org), Association France Ekbom (france-ekbom.fr).

---

Part 6 — Realistic timelines

• Iron, tablets or IV: judge at 12 weeks, never at 4 — the trial that missed at week 4 succeeded at week 12.
• Removing an aggravating drug: often days to two weeks.
• Exercise: 12 weeks minimum.
• A supervised taper: rebound peaks within days to two weeks of each reduction and usually settles over 2–8 weeks; withdrawal effects on mood can last months in some people.
• The whole plan: six to twelve months.

Two numbers that keep everyone honest. Across 85 trials the average improvement on placebo was 6.58 points on the 40-point scale, and about 6 points is what an individual needs to feel a real change (A) — so any improvement under roughly 6 points, from anything including this plan, is inside the noise. And in a ten-year Finnish study, about half of those with frequent RLS had rare or no symptoms a decade later with no treatment at all (B). Getting better does not prove what made you better.

---

Part 7 — Warning signs: contact your doctor promptly

• New or worsening thoughts of suicide or self-harm — RLS roughly doubles this risk and a taper is when it concentrates (B). Urgent, not wait-and-see.
• Panic, dread or depression out of proportion to your leg symptoms during a reduction — this is dopamine-agonist withdrawal syndrome; it resists going back on the drug and needs specialist input (D).
• New impulse-control behaviour out of character.
• Fainting on standing, a fall, or falling asleep during the day — stop driving and call.
• Symptoms much worse for more than two weeks after a reduction.
• Excess drowsiness or breathing trouble on a gabapentinoid and an opioid together.
• Bone pain or weakness after iron infusions — the phosphate problem; get it checked.

---

Full citations, PMIDs and evidence grades for every statement above are in docs/SOLUTION_PROTOCOL.md; the verification audit of those citations is in docs/SOLUTION_VERIFICATION.md. Bring docs/SOLUTION_CLINICIAN_SUMMARY.md to your appointment.